Device Trial Radar · NCT07592299
To Establish the Safety and Effectiveness of the ALPFA GRAIL PFA System for Treating Symptomatic Benign Prostate Hyperplasia (BPH) Also Known as an Enlarged Prostate.
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
250
Planned (sponsor's estimate)
Start
Oct 28, 2026
Primary completion
Oct 2027
Study completion Dec 2032
Sponsor
- Lead sponsor
- ALPFA MedicalNot on our public-company list
- Sponsor type
- Industry
- First posted
- May 18, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- Male only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main goal of this study is to evaluate the ALPFA GRAIL™ Pulsed Field Ablation (PFA) System for treatment of enlarged prostate (BPH) symptoms. The study will involve up to 250 male participants who have urinary problems caused by BPH and whom are greater than 40 years of age in up to 30 investigational centers across the US,Canada and European Union.
Conditions
- Benign Prostatic Hyperplasia (BPH)
Interventions
Treatment Device: The ALPFA Medical (ALPFA) GRAIL™ Pulsed Field Ablation (PFA) SystemDevice
After the participant receives anesthesia, the Investigator will proceed with placement of the ALPFA GRAIL PFA Catheter into the prostate via a standard flexible cystoscope. Visualization of the prostatic urethra will determine the number of balloons that are exposed and inflated. When the catheter has been properly positioned, the ALPFA GRAIL PFA Console will be activated and one PFA application will be delivered. The Investigator will assess if the catheter needs to be repositioned and additional ablation applications delivered, as necessary. Once ablation is complete, the catheter balloons will be deflated, and the catheter will be withdrawn from the urethra. Participants will then have follow-up visits with health checks as planned for this study.
Control Device: Sham flexible cystoscopyDevice
Participants will receive mock treatment with a flexible cystoscope with a working channel that is at least 6.9F in diameter. The cystoscope will be inserted and treatment script initiated. Once the script is completed, the cystoscope will be removed and procedural details captured on the relevant CRF. Participants will then have follow-up visits with health checks as planned for this study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety-Incidence of Serious Device-or Procedure-Related Adverse Events (Composite Safety Endpoint)Time frame: Through 12 months post-procedure
- Effectiveness-Change from Baseline in International Prostate Symptom Score (IPSS) at 3 Months.Time frame: Baseline to 3 months post-procedure
- Effectiveness-Durability of Treatment Effect: Percent Change in International Prostate Symptom Score (IPSS) at 12 MonthsTime frame: Baseline to 12 months post-procedure
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
East Valley Urology
Mesa, Arizona · Recruiting
Academic Urology & Urogynecology of Arizona
Sun City, Arizona · Recruiting
Del Sol Research Management
Tucson, Arizona · Not yet recruiting
15 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.